Pomalidomide combinations are a safe and effective option after daratumumab failure

PURPOSE: Outcomes of multiple myeloma (MM) patients who are refractory to daratumumab are dismal and no standard of treatment exists for this patients’ population. Here, we investigate the role of pomalidomide combinations in daratumumab-refractory MM patients. METHODS: We performed a retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Brioli, Annamaria, Gengenbach, Laura, Mancuso, Katia, Binder, Mascha, Ernst, Thomas, Heidel, Florian H., Stauch, Thomas, Zamagni, Elena, Hilgendorf, Inken, Hochhaus, Andreas, Engelhardt, Monika, von Lilienfeld-Toal, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356885/
https://www.ncbi.nlm.nih.gov/pubmed/36781500
http://dx.doi.org/10.1007/s00432-023-04637-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356885/
https://www.ncbi.nlm.nih.gov/pubmed/36781500
http://dx.doi.org/10.1007/s00432-023-04637-x

Ejemplares similares